Reading INAB? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track INAB free→Reading INAB? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track INAB free→QuarterlyIQ Insights · INAB
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Termination of a Material Definitive Agreement. As previously disclosed, on November 10, 2022 the Company entered into a Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co. (“ Cantor ”) as sales agent (the “ Cantor Sales Agreement ”), pursuant to which the Company was permitted to issue and sell, from time to time through Cantor, shares of the Company’s Common Stock. On May 29, 2026, the Company and Cantor mutually agreed to terminate the Cantor Sales Agreement and the…
Entry into a Material Definitive Agreement. On June 1, 2026, IN8bio, Inc. (the “ Company ”) entered into a Capital on Demand TM Sales Agreement (the “ Sales Agreement ”) with JonesTrading Institutional Services LLC (the “ Agent ”) with respect to an at the market offering program under which the Company may issue and sell, from time to time at its sole discretion, shares (the “ Placement Shares ”) of its common stock, par value $0.0001 per share (the “ Common Stock ”), through or to the Agent…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers As described in
Results of Operations and Financial Condition. On May 7, 2026, IN8bio, Inc. (the "Company") issued a press release announcing its financial results for the first quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended…
Results of Operations and Financial Condition. On March 12, 2026, IN8bio, Inc. (the “Company”) issued a press release announcing its financial results for fourth quarter and fiscal year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Form 8-K, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 26, 2026, Alan S. Roemer notified the Board of Directors (the “Board”) of IN8bio, Inc. (the “Company”) of his decision to resign as a director of the Board and as a member of the Audit and Compensation Committees of the Board, effective as of February 28, 2026. Mr. Roemer’s decision was not the result of any disagreement between Mr. Roe…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 4, 2026, the Company’s Board of Directors appointed Kate Rochlin, the Company’s Chief Operating Officer, as President of the Company, effective February 4, 2026. Dr. Rochlin will continue to serve as the Company’s Chief Operating Officer. Biographical information about Dr. Rochlin can be found in the section of the Company’s 2025 Proxy…
Unregistered Sales of Equity Securities. The information contained in
Entry into a Material Definitive Agreement. Securities Purchase Agreement On December 18, 2025, IN8bio, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (the “Investors”), pursuant to which the Company agreed to issue and sell shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”), and, in lieu of Common Stock, pre-funded warrants (the “Pre-Funded Warrants” and, together wi…
Results of Operations and Financial Condition. On November 6, 2025, IN8bio, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Form 8-K, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as…
Results of Operations and Financial Condition. On August 7, 2025, IN8bio, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Form 8-K, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amende…
Material Modification to Rights of Security Holders. (a) On June 3, 2025, IN8bio, Inc. (the “ Company ”) filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a reverse stock split at a ratio of 1-for-30 (the “ Charter Amendment ”). The Charter Amendment was authorized by the stockholders of the Company at the Company’s Annual Meeting of Stockholders held on May 8, 2025. Pursuant to the Charter…
Results of Operations and Financial Condition. On May 7, 2025, IN8bio, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Form 8-K, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (…
Unregistered Sales of Equity Securities. The descriptions of the Transactions, including the description of the Pre-Funded Warrants, in
Entry into a Material Definitive Agreement. Stock Purchase Agreement Amendment and Series B Warrant Amendment On April 27, 2025, IN8bio, Inc. (the “Company”) entered into an Amendment No. 1 (the “SPA Amendment”) to Securities Purchase Agreement, dated September 30, 2024 (the “Purchase Amendment”), to amend the restrictions on certain equity sales by the Company set forth in the Purchase Agreement. In consideration for the SPA Amendment, the Company will enter into amendments with certain hold…
Material Modification to Rights of Security Holders. The descriptions of the Series B Warrant Amendment and Warrant Exercises in
Results of Operations and Financial Condition. On March 13, 2025, IN8bio, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Form 8-K, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Ac…
Departure of Directors or Certain Officers. On March 4, 2025, Travis Whitfill notified the Board of Directors (the “Board”) of IN8bio, Inc. (the “Company”) of his resignation from the Board and its committees, effective as of May 9, 2025. Mr. Whitfill’s resignation is not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caus…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On February 5, 2025, IN8bio, Inc. (the “Company”) received a notice (the “Extension Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) informing the Company that Nasdaq granted the Company an additional 180 calendar days, or until August 4, 2025, to regain compliance with the minimum closing bid price requirement for continued listing on The Nasdaq Capita…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.